Chang Hsien-Yen, Boyd Cynthia M, Leff Bruce, Lemke Klaus W, Bodycombe David P, Weiner Jonathan P
*Department of Health Policy & Management †Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health ‡Department of Medicine, Division of Geriatric Medicine and Gerontology, School of Medicine, Johns Hopkins University §Center for Population Health Information Technology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Med Care. 2016 Sep;54(9):852-9. doi: 10.1097/MLR.0000000000000566.
High-cost users in a period may not incur high-cost utilization in the next period. Consistent high-cost users (CHUs) may be better targets for cost-saving interventions.
To compare the characteristics of CHUs (patients with plan-specific top 20% medical costs in all 4 half-year periods across 2008 and 2009) and point high-cost users (PHUs) (top users in 2008 alone), and to build claims-based models to identify CHUs.
This is a retrospective cohort study. Logistic regression was used to predict being CHUs. Independent variables were derived from 2007 claims; 5 models with different sets of independent variables (prior costs, medications, diagnoses, medications and diagnoses, medications and diagnoses and prior costs) were constructed.
Three-year continuous enrollees aged from 18 to 62 years old from a large administrative database with $100 or more yearly costs (N=1,721,992).
Correlation, overlap, and characteristics of top risk scorers derived from 5 CHUs models were presented. C-statistics, sensitivity, and positive predictive value were calculated.
CHUs were characterized by having increasing total and pharmacy costs over 2007-2009, and more baseline chronic and psychosocial conditions than PHUs. Individuals' risk scores derived from CHUs models were moderately correlated (∼0.6). The medication-only model performed better than the diagnosis-only model and the prior-cost model.
Five models identified different individuals as potential CHUs. The recurrent medication utilization and a high prevalence of chronic and psychosocial conditions are important in differentiating CHUs from PHUs. For cost-saving interventions with long-term impacts or focusing on medication, CHUs may be better targets.
某一时期的高成本使用者在下一时期可能不会产生高成本的医疗服务利用情况。持续高成本使用者(CHUs)可能是成本节约干预措施的更好目标。
比较持续高成本使用者(2008年和2009年所有4个半年期内特定计划医疗成本排名前20%的患者)和单点高成本使用者(仅在2008年为高成本使用者)的特征,并建立基于索赔的模型来识别持续高成本使用者。
这是一项回顾性队列研究。采用逻辑回归来预测成为持续高成本使用者的情况。自变量来自2007年的索赔数据;构建了5个具有不同自变量集(既往成本、药物、诊断、药物和诊断、药物和诊断以及既往成本)的模型。
来自一个大型行政数据库的18至62岁的三年连续参保者,年成本在100美元及以上(N = 1,721,992)。
呈现了从5个持续高成本使用者模型得出的最高风险评分者的相关性、重叠情况和特征。计算了C统计量、敏感性和阳性预测值。
持续高成本使用者的特点是在2007 - 2009年期间总费用和药房费用不断增加,且比单点高成本使用者有更多的基线慢性和社会心理疾病。从持续高成本使用者模型得出的个体风险评分具有中度相关性(约为0.6)。仅药物模型的表现优于仅诊断模型和既往成本模型。
5个模型识别出不同个体作为潜在的持续高成本使用者。反复的药物使用以及慢性和社会心理疾病的高患病率在区分持续高成本使用者和单点高成本使用者方面很重要。对于具有长期影响或侧重于药物的成本节约干预措施,持续高成本使用者可能是更好的目标。